Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2

Journal of Molecular and Cellular Cardiology
Jacqueline BräutigamRobert Fürst

Abstract

The process of angiogenesis is involved in several pathological conditions, such as tumor growth or age-related macular degeneration. Although the available anti-angiogenic drugs have improved the therapy of these diseases, major drawbacks, such as unwanted side effects and resistances, still exist. Consequently, the search for new anti-angiogenic substances is still ongoing. Narciclasine, a plant alkaloid from different members of the Amaryllidaceae family, has extensively been characterized as anti-tumor compound. Beyond the field of cancer, the compound has recently been shown to possess anti-inflammatory properties. Surprisingly, potential actions of narciclasine on endothelial cells in the context of angiogenesis have been neglected so far. Thus, we aimed to analyze the effects of narciclasine on angiogenic processes in vitro and in vivo and to elucidate the underlying mechanism. Narciclasine (100-300 nM) effectively inhibited the proliferation, undirected and directed migration, network formation and angiogenic sprouting of human primary endothelial cells. Moreover, narciclasine (1 mg/kg/day) strongly reduced the VEGF-triggered angiogenesis in vivo (Matrigel plug assay in mice). Narciclasine mediated its anti-angiogenic e...Continue Reading

References

Sep 1, 1985·Isis; an International Review Devoted to the History of Science and Its Cultural Influences·J M Riddle
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·E C KohnL A Liotta
Oct 1, 1993·Journal of Natural Products·G R PettitA W Meerow
Feb 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·D FukumuraR K Jain
Jun 14, 2002·Cardiovascular Research·Saeid Babaei, Duncan J Stewart
Oct 2, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Martin FaehlingJohannes Waltenberger
Jul 28, 2004·The Journal of Biological Chemistry·Seun-Ah YangCharles S Abrams
Dec 16, 2005·Nature·Peter Carmeliet
Apr 26, 2007·Angiogenesis·Carla CostaRaquel Soares
Jun 18, 2009·Molecular Cancer Therapeutics·Florence LefrancRobert Kiss
Jul 21, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Gwendoline Van GoietsenovenVéronique Mathieu
Jul 28, 2010·Apoptosis : an International Journal on Programmed Cell Death·Mustafa ArkBelgin Polat
Jan 5, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Ingo JustMarkus Hoeltje
Mar 26, 2011·Science·Christine L Chaffer, Robert A Weinberg
Oct 13, 2012·Nature Protocols·Ali ErtürkHans-Ulrich Dodt
Jan 9, 2013·The Journal of Cell Biology·Keith Burridge, Erika S Wittchen
Aug 22, 2013·British Journal of Pharmacology·Asmaa E El-Kenawi, Azza B El-Remessy
Sep 12, 2014·Nature·Nicolas Garreau de LoubresseMarat Yusupov
Jul 28, 2016·Nature Reviews. Molecular Cell Biology·Michael SimonsLena Claesson-Welsh
Nov 2, 2016·Development·Masahiro ShinNathan D Lawson
Sep 14, 2016·Journal of Cell Communication and Signaling·Chandran S AbhinandPerumana R Sudhakaran
Apr 25, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Anna StarkRobert Fürst

❮ Previous
Next ❯

Citations

Apr 19, 2021·Cancer Cell International·Yufei TangFenggang Hou
May 28, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·G Melissa KrishnathasIris Bischoff-Kont
Jun 1, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Luisa D Burgers, Robert Fürst
Jun 1, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Pelin ErkocRobert Fürst
Jul 22, 2021·Cancer Cell International·Yanming LuoHaiyang Yu
Nov 9, 2021·Frontiers in Oncology·Ruyi LiZhe-Sheng Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.